U.S. Biotech Stocks

Iovance Biotherapeutics

Market Cap: US$767.1m

A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.

Niagen Bioscience

Market Cap: US$760.8m

Operates as a bioscience company engages in developing healthy aging products.

Septerna

Market Cap: US$753.9m

A clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.

Mind Medicine (MindMed)

Market Cap: US$747.2m

A clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.

Xencor

Market Cap: US$746.8m

A clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer.

Akebia Therapeutics

Market Cap: US$734.5m

A biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.

ArriVent BioPharma

Market Cap: US$724.6m

A clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.

Myriad Genetics

Market Cap: US$718.3m

A molecular diagnostic testing and precision medicine company, develops and provides molecular tests.

Day One Biopharmaceuticals

Market Cap: US$703.7m

A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.

Maravai LifeSciences Holdings

Market Cap: US$694.6m

A life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.

Elite Pharmaceuticals

Market Cap: US$681.6m

A specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals.

Tyra Biosciences

Market Cap: US$680.1m

A clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.

Gyre Therapeutics

Market Cap: US$669.4m

A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.

Nurix Therapeutics

Market Cap: US$665.1m

A clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.

SNDL

Market Cap: US$661.4m

Engages in the production, distribution, and sale of cannabis products for the adult-use market in Canada.

KalVista Pharmaceuticals

Market Cap: US$653.3m

A biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.

Ginkgo Bioworks Holdings

Market Cap: US$639.1m

Develops a platform for cell programming in the United States.

SIGA Technologies

Market Cap: US$638.0m

A commercial-stage pharmaceutical company, focuses on the health security market in the United States.

Organogenesis Holdings

Market Cap: US$621.6m

A regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.

AnaptysBio

Market Cap: US$619.9m

A clinical-stage biotechnology company, focuses in delivering immunology therapeutics.

Bicara Therapeutics

Market Cap: US$610.6m

A clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.

Olema Pharmaceuticals

Market Cap: US$573.1m

A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.

Oruka Therapeutics

Market Cap: US$571.9m

A clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.

Arvinas

Market Cap: US$567.5m

A clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.

Arcturus Therapeutics Holdings

Market Cap: US$555.3m

Engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases.

Rigel Pharmaceuticals

Market Cap: US$543.1m

A biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.

Erasca

Market Cap: US$541.8m

A clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

Eton Pharmaceuticals

Market Cap: US$534.5m

A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.

Verastem

Market Cap: US$529.9m

A development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.

Zevra Therapeutics

Market Cap: US$502.4m

A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.

Standard BioTools

Market Cap: US$500.4m

Develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific.

Solid Biosciences

Market Cap: US$485.9m

Develops therapies for neuromuscular and cardiac diseases in the United States.

Corvus Pharmaceuticals

Market Cap: US$482.9m

A clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.

REGENXBIO

Market Cap: US$481.9m

A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.

Cryoport

Market Cap: US$478.6m

Provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.

Fulcrum Therapeutics

Market Cap: US$446.3m

A clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.